Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment22 Jun 2020
The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.
Catalent has signed an agreement with ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies, to develop a potential treatment for adults with advanced COVID-19. Specifically, the CDMO will focus on two oral dosage forms of ViralClear’s broad-spectrum antiviral agent, merimepodib: a solution and a solid oral dosage form.
ViralClear is undertaking research to investigate the potential of merimepodib to fight the SARS-CoV-2 virus, either as a standalone treatment, or in combination with other anti-viral agents or immune modulators.
Merimepodib, which was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals, is intended to be orally administered and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures.
Catalent has already manufactured clinical trial materials of ViralClear's merimepodib oral solution for the current Phase II clinical trial and is performing further product development on liquid-filled oral formulations.
Catalent will work on the program at its St Petersburg, Florida, facility, manufacturing oral solution for clinical studies, as well as undertaking feasibility studies on other liquid-filled oral formulations.
“Finding treatments for the pandemic we are faced with is a global priority, and, as a world leader in softgel development and manufacturing, Catalent is ideally suited to work on this program with ViralClear,” commented Dr Aris Gennadios, President, Softgel & Oral Technologies. “Our expertise and more than 85 years of experience in lipid-based formulation will facilitate rapid clinical manufacturing and provide drug product that can be tested against the threat the virus poses as soon as possible.”
SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment
7 Jul 2020
The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium.Read more
Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail
7 Jul 2020
The company began scaling up manufacturing of REGN-COV2 at business risk earlier this year to ensure the immediate availability of the product if clinical trials prove successful.Read more
Ajinomoto introduces fast track platform for drug product manufacturing
30 Jun 2020
AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.Read more
Piramal acquires solid oral dosage drug product facility from G&W Laboratories
22 Jun 2020
The site can also produce liquids, creams, and ointments, further expanding the CDMO's portfolio.Read more
Sanofi to build EUR 490 million vaccine production facility in France
16 Jun 2020
The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccinesRead more
Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's
8 Jun 2020
Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.Read more
Emergent bags $628 million "landmark" CDMO deal to produce COVID-19 vaccine candidates
2 Jun 2020
The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.Read more
Changes needed to prevent controversial pay-for-delay pharma deals
26 May 2020
Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.Read more
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient
26 May 2020
SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.Read more
AbCellera and Lilly seal multi-year antibody discovery collaboration
25 May 2020
AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation